Related Experiment Video

Updated: Aug 16, 2026

High-speed Video Microscopy Analysis for First-line Diagnosis of Primary Ciliary Dyskinesia
05:32

High-speed Video Microscopy Analysis for First-line Diagnosis of Primary Ciliary Dyskinesia

Published on: January 19, 2022

Congenital dyserythropoietic anemia type I (CDA I): molecular genetics, clinical appearance, and prognosis based on

Hermann Heimpel1, Klaus Schwarz, Monika Ebnöther

  • 1Department of Internal Medicine III, University of Ulm, Germany, Robert Koch Strasse 8, D-89081 Ulm, Germany. hermann.heimpel@medizin.uni-ulm.de

Blood
|September 6, 2005
PubMed

Insights

Congenital dyserythropoietic anemia type I (CDAI) is a rare genetic disorder. Long-term follow-up of 21 patients reveals variable anemia severity and highlights iron overload, with some responding to interferon alpha-2a therapy.

Area of Science:

  • Hematology
  • Genetics
  • Rare Diseases

Background:

  • Congenital dyserythropoietic anemia type I (CDAI) is a rare autosomal recessive disorder.
  • Characterized by ineffective erythropoiesis and iron overloading.
  • Limited data exists on the long-term evolution of CDA I.

Purpose of the Study:

  • To describe the lifetime evolution of CDA I.
  • To analyze clinical manifestations and treatment responses in a cohort of CDA I patients.
  • To investigate genotype-phenotype correlations in CDA I.

Main Methods:

  • Longitudinal follow-up of 21 CDA I patients from 19 families over up to 37 years.
  • Clinical data collection including anemia severity, complications, and treatment outcomes.
  • Genetic analysis of CDAN1 gene mutations in affected individuals.

Main Results:

  • CDAI patients exhibited chronic macrocytic anemia of variable severity; only 2 required regular transfusions.
  • Four patients developed gallstones before age 30.
  • Fifteen of 16 analyzed cases had mutations in CDAN1 exons 6-28.
  • Iron overloading was universal; iron depletion initiated between ages 7-36 in 9 patients.
  • Splenectomy did not improve hemoglobin levels.
  • Five patients treated with interferon alpha-2a showed a hemoglobin increase of 2.5-3.5 g/dL within 4 weeks.

Conclusions:

  • CDAI is a chronic condition with variable anemia requiring minimal transfusions in most cases.
  • Iron overload is a significant feature requiring management.
  • Interferon alpha-2a shows promise as a treatment for CDA I.
  • CDAN1 mutations are common in CDA I patients.

Related Concept Videos

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Pedigree Analysis01:35

Pedigree Analysis

Overview
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...